However, other factors (mainly related to driver gene alterations in lung cancer, such as EGFR and ALK) were not reported, as well as the information about treatment with targeted therapy for oncogene-addicted tumours (which may confound the results in the adenocarcinoma subset). Here, ALK is linked to lung carcinoma.